Studies blood and imaging markers in localized leiomyosarcoma patients receiving chemotherapy
Tests blood DNA and scan markers in people with localized leiomyosarcoma receiving chemotherapy.
Key facts
- Who runs it
- University of Michigan Rogel Cancer Center
- Where
- Ann Arbor, Nashville, and Rochester, United StatesSee the 3 sites
- Trial code
- Registry title
- Localized Leiomyosarcoma Biomarker Protocol
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 26 Apr 2023
- Expected to end
- Nov 2026
- Type of study
- Observational
- Treatments tested
- Blood and Tissue collection
- Record updated
- 2 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with leiomyosarcoma that has not spread, in the arm, leg, trunk wall or behind the belly. The tumor must be high-grade and larger than 5 cm (2 in).
- Age
- No age requirement.
- Sex
- All sexes can join.
- Disease stage
- Localized leiomyosarcoma of the extremity, body wall or retroperitoneum; grade 2 or 3, or high-grade; tumor larger than 5 cm (2 in) in greatest dimension; the main tumor can be removed completely by surgery.
- Earlier treatment
- The person must agree to receive doxorubicin and ifosfamide chemotherapy before surgery. If radiation is given before surgery, it must come after chemotherapy. Radiation after surgery is allowed.
- Biomarker or test result
- Stored tumor tissue from the diagnostic or pre-treatment biopsy must be available for research.
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients with localized leiomyosarcoma (LMS) of extremity, body wall or retroperitoneum
- Grade 2 or 3, or high-grade LMS
- Tumor size >5 cm in greatest dimension
- Primary tumor amenable to complete resection
- There is no age requirement
- Participant agrees to receive neoadjuvant doxorubicin and ifosfamide combination chemotherapy
- If pre-operative radiation is administered, it must be administered after chemotherapy. Post-operative radiation may be administered
- Archival tumor tissue (either frozen sample, tissue block containing tumor, or minimum of 4 unstained slides and 1 H\&E stained slide) from diagnostic or pre-treatment biopsy available for study research
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Scott Schuetze, MD/PhDTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Elizabeth J Davis, MDTaking people
- Mayo ClinicRochester, United StatesContact: Brittany Siontis, MDTaking people
About the trial
What the trial wants to find out
* Leiomyosarcoma (LMS) is one of the more common soft tissue sarcomas (STS). * Patients presenting with large, high-grade, localized LMS are at significant risk of developing metastasis following curative surgery. * Clinical trials of neoadjuvant or adjuvant anthracycline and ifosfamide have suggested that patients with localized STS who are at high-risk of metastasis may benefit from chemotherapy, but the magnitude of benefit in unselected patient population is relatively small. * Currently, patient age, and tumor size and grade are used to assess risk of metastases and survival * Studies evaluating tumor response by imaging and histopathology have not established correlation between tumor characteristics as biomarkers for risk of metastasis or sarcoma recurrence. * Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic LMS and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to, during and after chemotherapy and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Patients will be followed for 2 years after study entry for signs of sarcoma recurrence. * A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning.
Treatments tested
- Blood and Tissue collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of ctDNA and Imaging Characteristics as Biomarkers of Disease-related Outcomes in Patients With Localized Leiomyosarcoma Receiving Chemotherapy
- Plain-language title
- Studies blood and imaging markers in localized leiomyosarcoma patients receiving chemotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA.Clinical cancer research : an official journal of the American Association for Cancer Research, 2022
- Record updated
- 2 July 2026